Decades of scientific investment have paid off just in the last month, with researchers announcing promising breakthroughs ...

This virtual public workshop provided a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and to highlight opportunities ...

The goal of this collaborative is to examine and highlight the bottlenecks to drug research and development (R&D) for highly prevalent chronic diseases and develop a set of key considerations and ...

Increasingly, American innovators are curing or effectively eliminating the medical threat from many diseases and conditions.

Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025 CORALVILLE, ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In a move that could dramatically reshape the landscape for rare ...

Your editorial on “Why Vinay Prasad Had to Go at FDA” should be a wake-up call for anyone who cares whether federal bureaucrats get to decide if promising new medicines are available to desperately ...

My family's life changed the moment we learned our child was diagnosed with an SLC6A1-related disorder, a rare neurological ...

Frost & Sullivan, a global consulting and market research firm, has forecast that China's rare disease drug market will ...

LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, listed on the Hong Kong Stock Exchange on June 5, ...

This week, a House Judiciary subcommittee will hold a hearing to examine patents and prescription drug prices.